URGN•benzinga•
Reported Saturday, UroGen Pharma's UGN-102 Achieves 80.6% Probability Of Sustained Complete Response At 18 Months In Phase 3 ENVISION Trial
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 28, 2025 by benzinga